Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus

NCT01652729 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

365

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Type 2

Interventions

DRUG: Exenatide once weekly suspension
DRUG: Sitagliptin
DRUG: Placebo

Sponsor

AstraZeneca